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Non-Invasive Radiofrequency 
Field Treatment of 4T1 Breast 
Tumors Induces T-cell Dependent 
Inflammatory Response
Jared M. Newton1,2,3, Jose H. Flores-Arredondo1, Sarah Suki1, Matthew J. Ware1, Martyna 
Krzykawska-Serda  1,4, Mahdi Agha1, Justin J. Law1, Andrew G. Sikora2, Steven A. Curley1,5 & 
Stuart J. Corr1,6,7,8
Previous work using non-invasive radiofrequency field treatment (RFT) in cancer has demonstrated 
its therapeutic potential as it can increase intratumoral blood perfusion, localization of intravenously 
delivered drugs, and promote a hyperthermic intratumoral state. Despite the well-known immunologic 
benefits that febrile hyperthermia can induce, an investigation of how RFT could modulate the intra-
tumoral immune microenvironment had not been studied. Thus, using an established 4T1 breast cancer 
model in immune competent mice, we demonstrate that RFT induces a transient, localized, and T-cell 
dependent intratumoral inflammatory response. More specifically we show that multi- and singlet-
dose RFT promote an increase in tumor volume in immune competent Balb/c mice, which does not 
occur in athymic nude models. Further leukocyte subset analysis at 24, 48, and 120 hours after a single 
RFT show a rapid increase in tumoral trafficking of CD4+ and CD8+ T-cells 24 hours post-treatment. 
Additional serum cytokine analysis reveals an increase in numerous pro-inflammatory cytokines and 
chemokines associated with enhanced T-cell trafficking. Overall, these data demonstrate that non-
invasive RFT could be an effective immunomodulatory strategy in solid tumors, especially for enhancing 
the tumoral trafficking of lymphocytes, which is currently a major hindrance of numerous cancer 
immunotherapeutic strategies.
Solid tumor cancers currently make up over 85% of new cancer cases and result in over 90% of all cancer-related 
deaths in the United States1. Despite promising advances in cancer oncology many solid tumors pose a major 
challenge, often resulting in the use of aggressive treatment schedules, which expose patients to dangerous, poten-
tially deadly, treatment regimens with considerable side-effects. This has lead the field to seek alternative treat-
ment options for solid tumor malignancies and immunotherapy is currently a promising area of investigation. 
Immunotherapies hold substantial potential as a treatment platform for solid tumors, largely because they pro-
vide semi-selective targeting of cancer cells, the ability to attack both local and disseminated disease, and features 
of immunologic memory, which can recognize and eliminate instances of recurrence. These unique abilities of 
immunotherapy make it an increasingly attractive treatment strategy in solid tumor therapy.
Despite extensive efforts however, immunotherapies currently only promote long-term survival benefits in a 
small subset of patients with solid tumor malignancies2–4. Many groups propose that various tumor factors are 
primarily responsible for this lack of efficacy. The first problem is the tumor microenvironment, a highly immu-
nosuppressive environment composed of a variety of regulatory cell types such as myeloid-derived suppressor 
cells (MDSC) and T-regulatory cells (Treg), which mitigate any potential effector immune responses infiltrating 
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the tumor5. Multiple groups have further suggested that tumors possess high intra-tumoral interstitial pressure 
and high levels of hypoxia due to inadequate blood vascularization which significantly hinders various cells of the 
immune system from reaching the internal recesses of the tumor6–8.
Non-invasive radiofrequency field treatment (RFT) has been previously investigated by our group and others as 
a potential therapy in both pancreatic ductal adenocarcinoma (PDAC) and hepatocellular carcinoma (HCC)9–11. 
Further characterization of the effects of RFT within in vitro systems suggests that RFT induces changes in 
cell-cell adhesion, elasticity, and morphology, which could significantly change the physical characteristics of the 
tumor microenvironment12,13. Our group has additionally shown that single dose-RFT can enhance intra-tumoral 
blood flow and perfusion of intravenously delivered nanoparticle probes14,15. More recently we demonstrated 
that consecutive RFT doses across a range of treatment temperatures (37–43 °C) could enhance intravenously 
delivered fluorescent probes, suggesting that RFT could improve intratumoral drug delivery. Results from this 
study further suggested that RFT promoted a unique form of tumor hyperthermia, with drastic improvements in 
temperature differential (i.e. internal tumor temperature vs. systemic body temperature), uniform tumor heat-
ing, post-treatment intra-tumoral blood velocity, and overall safety compared to contact-convectively delivered 
hyperthermia treatment16. Thus, RFT proved to be a safe and optimal method for exposing the tumor to hyper-
thermic conditions.
Hyperthermia has long been a topic of interest in cancer with treatment history dating back to Hippocrates in 
ancient Greece17. Systemic hyperthermia in the febrile range (38 °C –42 °C) has been previously investigated for 
its chemo- and radiotherapy sensitizing properties, which improved clinical outcomes in a randomized clinical 
trial18. With recent technological developments, a number of studies have investigated more localized hyperther-
mia effects including isolated limb, intraperitoneal, and thoracic cavity heating, and observed promising enhance-
ments in tumor treatment sensitivity19,20. In addition to radio- and chemo-sensitizing properties, hyperthermia 
is also known to promote a variety of favorable intratumoral immunologic effects21. Several potential treatment 
mechanisms have been suggested, including the ability of febrile range hyperthermia to improve tumor oxy-
genation: a critical hurdle of immune attack of solid tumors, as hypoxic conditions are known to promote many 
immunosuppressive effects8,22.
In addition to re-oxygenation, numerous studies have suggested that mild hyperthermia can promote effector 
immune cell tumoral trafficking, with some reported cases showing a greater than 5-fold increase in cytotoxic 
T cells infiltrating the tumor microenvironment23. Although the mechanism of this enhanced infiltration still 
remains somewhat unclear, prior data would suggest that the mild hyperthermia is able to drive various fea-
tures which favor lymphocyte infiltration and attack of solid tumors; including increasing expression of ves-
sel wall binding domains such as intercellular adhesion molecule-1 (ICAM-1)24, promoting a more favorable 
intratumoral interstitial pressure25, and driving the production of a number of pro-inflammatory cytokines and 
chemokines (i.e. interleukin (IL)−1β, IL-6, IL-8, IL-10) which have major implications in T-cell activation and 
trafficking26,27. Despite the vast amount of work done to investigate intratumoral hyperthermia immunologic 
effects, most studies rely on either systemic or convectively delivered hyperthermia. Based on our prior data, we 
have demonstrated that RFT can provide more localized, uniform, and safe intratumoral hyperthermia; however, 
an investigation of immunologic effects following febrile range RFT hyperthermia remains unstudied.
Therefore, the objective of this work was to characterize the immunologic changes induced by RFT with a 
particular focus on intratumoral immune microenvironment changes. We hypothesized that RFT would induce 
significant intra-tumoral immune changes particularly through pro-inflammatory mechanisms. Using immune 
competent Balb/c mice bearing 4T1 breast tumors we investigated both consecutive RFT dosing schedules and 
single-dose time-course investigations to better understand the transient immunologic changes induced by RFT.
Results and Discussion
Using the protocol developed in our previous study16, either Balb/c or athymic nude Balb/c mice bearing 4T1 
tumors were treated with multiple doses of RFT. During treatment, tumor surface temperatures were increased 
to 41 °C and maintained there for 30 mins and systemic temperature of each mouse was measured using a rectally 
inserted fiber optic temperature probe. Using this method allowed for effective and consistent heating of tumor 
tissue and only minor systemic heating (Fig. 1a–c; Supplementary Figure S1A). Based on previous published 
work this would be consistent with a 40–41 °C internal tumor temperature, as RFT results in a less than 1 °C tem-
perature differential between superficial and intra-tumoral temperature16. Control treated mice were placed on 
a heating pad under isoflurane to maintain similar systemic temperatures as the RFT mice, to better investigate 
the localized heating effects.
RFT or control mice, either Balb/c or athymic nude Balb/c, bearing established 4T1 tumors underwent 
numerous consecutive treatments every 3 days and tumor growth was measured throughout. Of interest, the RFT 
Balb/c mice demonstrated a significant increase in tumor volume compared to control Balb/c mice after 4 total 
radiofrequency (RF) doses (Fig. 2a). This increase in tumor volume was not observed in the immunodeficient 
athymic nude Balb/c mice bearing similarly established 4T1 tumors following multiple RFT (Fig. 2b). Histologic 
analysis of these tumors revealed no major changes between the RF and control treated mice and quantification 
of tumor necrotic fraction revealed similar necrosis between both groups (Fig. 2c). In addition, Ki67 staining for 
tumoral proliferation showed similar levels between control and RF treated groups (Fig. 2d; see Supplementary 
Figure S3A,B for full set of images). Both control and RF treated groups showed strong proliferation in the outer 
tumor periphery as expected per this aggressive 4T1 tumor model (Fig. 2d). Furthermore, although only mouse 
body weight was directly assessed, there were no obvious differences between RFT and control groups to suggest 
treatment-related toxicities (Supplementary Figure S1). In addition, we noted no signs of metastases at termina-
tion, and similar lung weights between RF and control mice further suggest no increase in metastatic potential 
following RFT (Supplementary Figure S1C). Collectively, these data suggest that RFT induced an inflammatory 
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response within tumors that required functional T-cells and that this immunologic effect was primarily responsi-
ble for the change in tumor volume after multiple doses of RFT.
To better characterize the immunologic changes induced by RFT, an immune microenvironment analysis 
of tumor, spleen, blood, and tumor-draining inguinal lymph node was performed (see Supplemental Figs S4 
and S5 for flow gating strategy). For these studies immune competent Balb/c mice with established 4T1 tumors 
were treated with a single dose of RFT. Tissues were then processed and analyzed either 24, 48, or 120 hours after 
single-dose RFT. Similar to multi-RFT tumor growth characteristics, single-dose RFT tumors also displayed a 
transient tumor volume increase. RFT treated tumors showed a 50% increase in measured volume by 24 hours 
post-RFT which remained significantly larger than control tumors until 72 hours post-RFT, after which they 
returned to control tumor sizes (Fig. 3a). Immune microenvironment analysis further showed a transient tumoral 
influx of CD4+ and CD8+ T-cells which were increased by greater than 3- and 4-fold in RFT treated tumors 
24 hours after treatment, respectively (Fig. 3b,c). Increased T-cell levels returned to control levels by 48 hours 
after RFT. Analysis of tumor-draining inguinal lymph nodes showed an inverse effect as they appear entirely 
devoid of T-cells 24 hours post-RFT, but significantly increase more than 38- and 36-fold for CD4+ and CD8+ 
T-cells, respectively, by 120 hours post-RFT (Fig. 3c). These data suggest that lymph-node dwelling T-cells are 
being drawn to the tumor rapidly after RFT is applied, rendering the lymph node devoid of lymphocytes. In 
addition, it would appear that the increases in T-cell trafficking following RFT are time-dependent, potentially 
peaking near 24 hours post-RFT. One potential factor that could be limiting further lymphocyte trafficking into 
tumors that received RFT is the 2-fold increase in MDSC at 120 hours post-RFT compared to control tumors 
(Fig. 3d). MDSC are well-known to employ a number of immunosuppressive mechanisms that can significantly 
inhibit the infiltration of lymphocytes into the tumor microenvironment5. Thus, the increased MDSC may con-
tribute to the build-up of T-cells within the lymph node as they inhibit further T-cell infiltration to the tumor 
microenvironment.
Splenic and hematologic changes appeared quite minor with only slight decreases in CD4+ T-cells, CD8+ 
T-cells, and macrophages in the blood at 24 hours post-RFT, which could be explained by the observed trafficking 
and other tumoral effects of RFT (Supplementary Tables 1–4). In addition, the activation state of tumor dwelling 
CD8+ T-cells was also significantly reduced at 48 hours post-RFT, as they expressed lower levels of Perforin and 
IFNγ, two T-cell effector molecules (Supplementary Figure S2). The immunologic effects of RFT appear to be 
highly localized to the site of treatment, with only minor systemic alterations. Therapeutically this could provide 
an advantage to many other immunomodulatory treatments, which have concerning systemic toxicities, usually 
involving systemic hyperactivation and concerns of cytokine storm. Overall, our data would suggest that RFT can 
provide a highly localized and transient influx of lymphocytes which, if combined with other lymphocyte-focused 
immunotherapeutic strategies, will likely provide major combinatorial therapeutic benefit.
Figure 1. RFT set-up and temperature monitoring. (a) Schematic depicting capacitively-coupled 
radiofrequency (RF) transmitting and receiving head showing mouse orientation and copper blanket shielding. 
(b) Image of mouse grounding and shielding showing exposed tumor (green arrow) and rectally inserted 
fiber-optic probe (red arrow) used for systemic temperature monitoring. Representative graph to the right 
shows systemic temperature measurement for a single mouse during an entire RFT session. (c) Image from 
infrared camera showing exposed tumor used for tumor surface temperature monitoring. Representative graph 
to the right shows tumor surface temperature measurement for a single mouse during an entire RFT session. 
(Supplemental Figure S1 shows cumulative treatment systemic and tumor surface heating curves).
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Due to the vast amount of previous evidence suggesting that key pro-inflammatory cytokine and chemokine 
expression following febrile hyperthermia promote T-cell infiltration26,27, we investigated whether RFT induced 
any significant changes in serum cytokine levels. Blood collected at 24, 48, and 120 hours after a single RFT 
were compared across a pro-inflammatory panel of 25 cytokines and chemokines. Similar to previous results we 
observed a highly transient cytokine response, with noted increases 24 hours after RFT in a number of proin-
flammatory cytokines including IL-6, IL-17, IP-10, IL-12(p70), MIP2, and RANTES (Fig. 4a). IL-6 appeared the 
most drastically elevated, with a 6-fold increase induced 24-hours after a single dose of RFT (Fig. 4b). Despite 
the negative effects that IL-6 is known to induce in tumors, previous evidence would suggest that IL-6 alters its 
function under period of hyperthermic stress and strongly promotes T-cell activation and enhanced infiltration26.
While modest, a significant increase was also noted in MIP2 (i.e. CXCL2), a potent chemoattractant for leu-
kocytes (Fig. 4b). This along with the other modest increases in chemokines such as RANTES (i.e. CXCL5) and 
IP-10 (i.e. CXCL10) could collectively contribute to the enhanced infiltration of T-cells by 24-hours post-RFT. 
Figure 2. Consecutive-dose RFT induces T-cell dependent tumor growth effect with no effects on tumor 
necrosis or proliferation. 4T1 tumor volume following multiple consecutive RFT (41 °C, 30 mins; date of 
treatment indicated by black arrows) in either (a) wild-type Balb/c mice or (b) athymic nude Balb/c mice 
(n = 10/group). (c) Representative H&E histology images of control (top) and RF-treated (bottom) tumors at 
termination (black arrow denotes necrotic region), with zoom-in of necrotic region to the right. Quantification 
of necrotic fraction is provided to the far right comparing RF-treated and control mice (n = 5–6/group). 
(d) Representative IHC images showing Ki67 expression comparison between control (top) and RF-treated 
(bottom) tumors, with zoom-in of highly proliferative tumor periphery to the right. Quantification of Ki67+ 
tumor fraction is provided to the far right comparing RF-treated and control mice (n = 5–6/group). Error bars 
represent SEM. (See Supplemental Figure S3 for complete image set). (*p < 0.05, **p < 0.01, ***p < 0.001).
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On the other hand, G-CSF, a cytokine commonly released by endothelium and macrophages, underwent a 
2.5-fold reduction 24-hours after RFT. This observation was further supported by the microenvironment analysis 
which showed that intra-tumoral macrophage were almost entirely depleted 24 hours post-RFT (Supplementary 
Figure S2). Since this depletion was not associated with increased trafficking to the draining lymph node, this 
would suggest that tumor dwelling macrophages may have a lower tolerance for hyperthermia conditions result-
ing in their depletion. Interestingly, all elevated cytokines and chemokines appear to return to baseline levels 
by 48 hours post-RFT, with the exception of IL-2, which modestly increases at 48 hours post-RFT. The transient 
nature of the cytokine and chemokines directly corroborates our microenvironment analysis, which showed the 
most potent intratumoral infiltration effects at 24 hours post-RFT. Overall, these data further suggest a tran-
sient immunologic effect induced by RFT, and suggest that the enhanced T-cell tumoral infiltration could be 
due at least in part by increased expression of a number of proinflammatory cytokines and leukocyte attractive 
chemokines.
Conclusion
With the emergence of immunotherapy as a promising cancer treatment modality there remains an evident 
need for immunomodulatory strategies capable of promoting effector immune cell trafficking and infiltration 
into solid tumors. The use of non-invasive RFT, despite previously having been shown to promote effective and 
Figure 3. Immune microenvironment time-course analysis following single-dose RFT. (a) 4T1 tumor volume 
in Balb/c mice following single RFT (41 °C, 30 mins; day of treatment indicated by black arrow) which were 
terminated for microenvironment analysis at either 24hrs (left), 48hrs (middle), or 120hrs (right) post-RFT 
(n = 5/group). (b) Representative flow cytometry scatter plots among CD45+ cells showing the increase in 
CD4+ and CD8+ T cell populations in tumor between a control and RF-treated mice 24 hours post-RFT. (c) 
Cumulative plots of CD4+ T cell percentages (top row) and CD8+ T cell percentages (bottom row) showing 
changes in T cell percentages among total viable cells 24hrs post-treatment for tumor (left column) and changes 
24, 48, and 120hrs post-treatment in tumor-draining lymph node (right column). (n = 3–10/group). (d) Control 
vs. RF-treated tumor percentage of MDSC (CD11b+/Gr1+) 120hrs post-treatment with representative flow 
plots (left) and cumulative plots showing percentages among total viable cells (right) (n = 5–10/group). See 
Supplemental Figs S4 and S5 for flow cytometry gating strategy. Each point represents an individual mouse 
percentage and all percentages are out of total viable cells analzyed. Error bars represent SEM. (*p < 0.05, 
**p < 0.01, ***p < 0.001, ****p < 0.0001).
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safe intratumoral hyperthermia, has never been fully investigated for its immunomodulatory potential. Herein 
we described the immunomodulatory effects of RFT on a 4T1 murine breast tumor model. We observed that 
RFT-induced hyperthermia drives a highly localized and transient intra-tumoral inflammatory response. This 
effect promoted a 3- and 4-fold increase in the intra-tumoral infiltration of CD4+ and CD8+ T-cells, respectively, 
24 hours after a single RFT was applied. This effect was further manifested as a transient tumor volume increase, 
which remained significantly larger than control tumors up to 72 hours after a single RFT was applied.
The transient increase in tumor volume that was noted following either single or multiple dose RFT could 
be associated with previous reports of febrile range hyperthermia in solid tumors that have noted similar tran-
sient tumoral swelling occurring shortly after treatment; however, a proper assessment of causation was not 
performed28,29. In addition, numerous reports have suggested that febrile hyperthermia can increase intratu-
moral blood perfusion, which could cause increased fluid accumulation and tumor distention30. It has also been 
suggested that hyperthermia treatment of cancer cells can promote increased rates of DNA damage31,32, which 
could contribute to delayed tumor volume reduction. All of these reports suggest likely contributing factors to 
tumor volume enlargement following hyperthermia, however, our data would suggest that local T-cell infiltration 
plays a contributing role. As support of this claim, we observed significant increases in both CD4+ and CD8+ 
T-cells within the same duration as the noted tumor enlargement. In addition, the increase in tumor size was not 
observed in similarly treated athymic nude Balb/c mice, which suggests that functional T-cells are a necessary 
component of the tumor enlargement phenomenon in this 4T1 murine tumor model. Finally, the observation 
that neither tumor proliferation or tumor necrosis increased following multiple dose RFT compared to control 
tumors further suggests that the enlargement was independent of the tumor cell features themselves. Thus, our 
data suggests that T-cell infiltration and induced inflammation could contribute to transient increases in tumor 
volume following RFT hyperthermia of solid tumors.
We further provide some potential mechanistic insights for the increased lymphocytes trafficking as various 
cytokines associated with inflammation and T-cell trafficking were elevated in RFT mice, especially IL-6. Despite 
these promising effects however, treatment efficacy of RFT alone was not observed, even after multiple consecu-
tive doses. This limitation is likely related to numerous factors including; 1) the lack of tumor-specific and effector 
T-cell generation, 2) increased trafficking of immunosuppressive MDSC populations after RFT, 3) T-cell exhaus-
tion or lack of critical lymphocyte signaling, and 4) persistent expression of immunosuppressive molecules by 
malignant cells. This highlights the need to further combine RFT with other immunotherapeutic strategies, which 
could promote lymphocyte activation, enhance T-cell tumor specificity, and prevent exhaustion; such as immune 
checkpoint inhibitors, chimeric antigen receptor (CAR) T-cells, and cancer vaccine strategies.
Overall, these data demonstrate that non-invasive RFT may provide an effective transient immunomodulatory 
method in solid tumor cancers, and its combination with other immunotherapeutic strategies will likely provide 
significant combinatorial therapeutic benefit. Future experimental work will focus on repeated RFT to maintain 
higher levels of effector T cells in the tumor microenvironment and on studying improved immunotherapy-based 
cancer cell cytotoxicity while co-treating with checkpoint inhibitors and other immunomodulators.
Materials and Methods
Ethic statement and general mice conditions. All experiments were performed with approval of the 
Institutional Animal Care and Use Committee (IACUC) of Baylor College of Medicine (No. AN-6445) and fol-
lowed established protocols. Female Balb/c or athymic nude Balb/c mice (Jackson Labs) were housed in standard 
temperature and lighting conditions with free access to food and water. RFT was performed under isoflurane 
anesthesia (0.7–2.5% isoflurane in medical air). During anesthesia, systemic mouse temperature was monitored 
using a rectally inserted fiber optic temperature probe and breathing frequency was maintained at approximately 
Figure 4. Blood plasma cytokine panel time-course analysis following single-dose RFT. At 24, 48, or 120 hrs 
after a single RFT blood plasma was analyzed for 25 cytokines. (a) Cytokine plasma concentration fold-change 
of RF-treated mice at 24, 48, or 120 hours post-RFT compared to control mice. Fold changes for each analyte 
were calculated by taking the ratio of average plasma concentrations of RFT-mice and control mice for each 
independent time-point (i.e. [G-CSF]24 hr RF/[G-CSF]24 hr Control) (n = 5/group). (b) Plasma concentration in pg/
mL of IL-6 (top) and MIP2 (bottom) comparing control and RF-treated mice 24hrs post-RFT (n = 5/group). 
Error bars represent SEM. (*p < 0.05).
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1 Hz by adjusting isoflurane concentration and/or flow rate. After anesthesia and treatment mice were kept in a 
pre-warmed chamber until complete recovery.
Tumor model. 4T1 cells were purchased from American Type Cell Culture (ATCC; Rockville, MD) and were 
cultured in RPMI 1640 media supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. 
Cells were cultured in a humidified atmosphere at 37 °C and 5% CO2. 105 4T1 breast cancer cells suspended in 
base medium were injected into the left inguinal gland (27 G needle, 50 µL injection volume) to initiate orthotopic 
4T1 breast tumors in Balb/c mice (wildtype or athymic nude). Treatment (RF or control) was initiated between 
12–15 days of tumor development when tumors had reached 100–200 mm3 in volume. All tumor measurements 
were performed using calipers and volume was calculated using Equation 1, where W = tumor width, L = tumor 
length, and H = tumor height.
π
= ∗ ∗ ∗V L W H
6 (1)
Radiofrequency field treatment (RFT). For a single dose of RFT anesthetized mice were grounded and 
shielded using copper tape to ensure localized RFT at the tumor site. Mice were then subjected to high inten-
sity (~90 kV/m) 13.56 MHz RF fields at various powers (0–1000 W) to administer a bi-phasic thermal dose that 
included a ‘ramp up’ phase from baseline tumor surface temperature to 41 °C and a second ‘plateau’ phase which 
maintained tumor surface temperature at 41 °C for 30 mins. Non-RF “control” mice were similarly anesthetized 
and placed on a heating pad to achieve similar levels of systemic heating without the addition of RFT. Systemic 
temperature and tumor surface temperature were measured using a rectally inserted fiber optic thermal probe 
and an infrared camera, respectively (for treatment set up see Fig. 1a–c). For both control and RFT mice, the skin 
on and around the tumor were shaved prior to treatment to allow for accurate tumor surface temperature assess-
ment throughout treatment. All inoculated mice were randomized prior to treatment and the tumor measure-
ments were performed with proper blinding. Before experiments were performed, the IR camera and fiber optic 
probes were calibrated using a water-bath (data not shown) to ensure accurate thermometry.
Multiple dose RFT. Consecutive doses of RFT or control treatment were performed in established 4T1 breast 
tumors in Balb/c mice (wildtype or athymic nude) as described above and in our previous work16. After tumors 
reached size requirements treatment was initiated and repeated every 3 days for a total of 4–5 doses. Growth 
assessment was terminated between day 28–30 post-tumor inoculation.
Tissue Sectioning and Histology. At termination, tumors were isolated, frozen in O.C.T (Tissue-Tek), and stored 
at −80 °C prior to histologic sectioning and staining. Frozen sections were cut at −20 °C at 6 µm thickness and 
picked up on positively charged slides. Slides undergoing hematoxylin and eosin (H&E) staining were fixed in 
95% ethyl alcohol for 2 minutes prior to standard H&E staining. Unstained slides were stored at −80 °C until 
further processing.
Ki67 immunohistochemistry. Slides were fixed in chilled acetone for 20 minute prior to staining. Heat-induced 
epitope retrieval was performed using a Biocare Decloaking chamber and Rodent Decloaking solution at 125 °C 
for 30 minutes (Biocare Medical, LLC). Slides then underwent primary Ki67 antibody incubation for 30 minutes, 
MACH2 universal detection incubation for 30 minutes, and Betazoid DAB chromogen for 5 minutes, with thor-
ough washing using Tris-buffered saline between each incubation. After the final rinse, slides were background 
stained using CAT hematoxylin for 5 minutes. Fully stained slides were thoroughly rinsed and dehydrated using 
an ethanol gradient series prior to coverslipping.
Microscopic imaging of histology. All brightfield imaging was performed using a Nikon Eclipse TE2000-U 
microscope fitted with a Nikon digital sight DS-Fi1 camera. Image analysis was performed using ImageJ software 
(National Institutes of Health, USA).
Single dose RFT Time-course. A single dose of RFT or control treatment was delivered at day 12 post-tumor 
inoculation and leukocyte subset analyses of tumor, spleen, blood, and tumor draining inguinal lymph node was per-
formed at 24, 48, or 120 hrs after the single treatment.
Tissue preparation. At termination, tumor, spleen, blood, and tumor draining inguinal lymph node was har-
vested. Tumor was manually chopped into pieces and digested in base media containing 1 mg/mL Collagenase 
I (Sigma) for 1 hr at 37 °C with gentle shaking throughout. At 1 hr, digestions were immediately ceased with the 
addition of media containing 2% FBS. Digested tumors, spleens, and lymph nodes were passed through a 30 µm 
cell strainer to obtain single cell suspensions. Blood was collected via cardiac puncture and split between a tube 
containing EDTA to prevent clotting (for microenvironment analysis) and a free tube, which was allowed to clot 
at room temperature (for serum cytokine collection). Single cell suspension of spleen and EDTA-containing 
blood underwent red blood cell lysis using LCK lysis buffer per manufacturer’s instructions. Clotted blood from 
the free tube was centrifuged (2000 × g, 10 mins) and supernatant serum was collected and stored at −80 °C prior 
to analysis.
Staining and Flow cytometry. Single cell suspensions for microenvironment analysis were stained for flow cyto-
metric analysis using either a lymphocyte or myeloid staining panel. Antibodies for the lymphocyte panel are as 
follows; CD45 APC-eFluor780, CD4 PE-Cy5, CD8a eFluor450, NK1.1 AF700, PD-1 PerCP-eFluor710, CTLA-4 
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PE, IFNγ PE-eFluor610, Granzyme B eFluor660, Perforin FITC, and FoxP3 PE-Cy7. Antibodies for the myeloid 
panel are as follows; CD45 APC-eFluor780, F4/80 eFluor450, CD11b APC, PD-L1 PE-Cy7, iNOS FITC, CD11c 
PE-Cy5.5, MHCII PE, Ly6G (Gr1) AF700. All antibodies were purchased from Ebiosciences except iNOS which 
was purchased from BD Bioscience. Both panels optimized a viability stain, FVS510 (BD Biosciences). For stain-
ing, cells were first stained with viability stain, rinsed, and blocked in Fc Block (BD Bioscience) per manufactur-
er’s instructions. Extracellular staining was performed in 100 µL total staining volume protected from light for 
30 mins at 4 °C. Cells were then rinsed and fixed/permeabilized (Fix/Perm buffer eBioscience) at 4 °C overnight. 
The following day cells were rinsed and resuspended in Perm buffer (eBioscience), stained for intracellular mark-
ers (30 mins at 4 °C), rinsed, and resuspended in FACs buffer (PBS + 2% FBS) for flow cytometry analysis using 
an LSR II flow cytometer (BD Bioscience). Flow cytometry analysis was performed using FlowJo v10 (FlowJo, 
LLC; Ashland, OR). For all cell types analyzed percentages were recorded as percent of total viable cells analyzed 
because a similar number of total viable cells were recorded between each sample (see Supplemental Figs S4 and 
S5 for gating strategy for lymphocyte and myeloid panels, respectively).
Serum Cytokine Analysis. Serum cytokine analysis optimized a 25-plex mouse cytokine/chemokine magnetic 
bead panel (EMD Millipore). Cytokines/chemokines assayed include G-CSF, GM-CSF, IFNγ, IL-1α, IL-1β, IL-2, 
IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17, IP-10, KC, MCP-1, MIP-1α, 
MIP-1β, MIP-2, RANTES, and TNF-α. Samples were prepared via manufacturer’s instructions and analysis was 
performed using a Luminex LX200 (Luminex Corp. Austin, TX).
Experimental design and data analysis. All experiments were done with proper blinding and rand-
omization. For all experiments GraphPad Prism version 7.00 for Windows (La Jolla, CA) was used for graph 
generation and statistical analysis. Normal data distribution was verified by Shapiro-Wilk test prior to com-
parisons. Bi-comparisons (i.e. RFT vs. control) were statistically compared using an unpaired student’s t-test. 
Multi-comparisons (i.e. tumor growth curves, serum cytokine analysis) were performed using a 2-way ANOVA 
with Bonferroni-corrected multi-comparison. For all comparisons, a p-value less than 0.05 was considered 
statistically significant and the following p-value representations were used throughout; *p < 0.05, **p < 0.01, 
***p < 0.001, ****p < 0.0001.
Data Availability. The datasets generated during and/or analyzed during the current study are largely 
included in this published article (and its Supplementary Information files) and any other datasets generated not 
included in this article are available from the corresponding author on reasonable request.
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